Plasmalogen Therapy

Plasmalogens are naturally occurring compounds in your body that act as a shield for nerve cells in your brain and body. They are also vital in maintaining cognitive function. Plasmalogens are essential phospholipids that research has identified as crucial players in brain health and potential therapeutic targets for neurodegenerative conditions. As we age, our natural plasmalogen levels decline, potentially contributing to cognitive challenges and neurological disorders. Emerging research suggests that restoring these vital compounds may offer new hope for maintaining brain health and potentially slowing age-related cognitive decline.

Key findings show that:

• Plasmalogen levels are significantly reduced in Alzheimer's and Parkinson's patients
• Higher plasmalogen levels correlate with better cognitive performance in aging populations
• Supplementation has shown promising results in early clinical trials
• These compounds play multiple protective roles in brain cell function and maintenance

We utilize the Prodrome-NE blood test which allows us to assess your current plasmalogen levels as well as your body’s capacity to produce them. The Prodrome Scan test uses ion cyclotron resonance mass spectrometry to measure over 40 different biomarker levels for a comprehensive assessment of the critical biochemical systems in our bodies. Most importantly, it measures brain-specific plasmalogen lipids that correlate with neurological health and cognitive decline. This blood biomarker test can detect early warning signs of neurodegenerative conditions, potentially years before clinical symptoms appear, allowing for earlier intervention and preventive measures against conditions like Alzheimer's disease. 

Recent breakthroughs in research have made it possible to restore healthy plasmalogen levels through supplementation with a patented form of plasmalogen precursors. 

Several clinical trials have demonstrated the efficacy of plasmalogen therapy in humans:

• A randomized controlled trial showed that plasmalogens improved cognitive function in patients with mild Alzheimer's disease (AD) or mild cognitive impairment
• Improvement in cognitive function was also observed in patients with moderate to severe AD
• Patients with Parkinson's disease showed cognitive improvements with plasmalogen supplementation

Fujino M, Fukuda J, Isogai H, Ogaki T, Mawatari S, Takaki A, Wakana C, Fujino T. Orally Administered Plasmalogens Alleviate Negative Mood States and Enhance Mental Concentration: A Randomized, Double-Blind, Placebo-Controlled Trial. Front Cell Dev Biol. 2022 Jun 2;10:894734. doi: 10.3389/fcell.2022.894734. PMID: 35721497; PMCID: PMC9203127.

Safety Profile

• Generally recognized as safe in clinical trials
• Well-tolerated in long-term studies
• Minimal reported side effects
• Natural presence in human tissue supports biocompatibility

Therapeutic Considerations

• Early intervention may provide better outcomes
• Individual response variation requires monitoring
• Regular assessment of cognitive function recommended
• Potential interaction with other medications should be evaluated